BAAM
IONS icon

Baker Avenue Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Baker Avenue Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-77
Closed -$3.49K – 900
2023
Q3 		$3.49K Hold
77
– – ﹤0.01% 1021
2023
Q2 		$3.16K Hold
77
– – ﹤0.01% 907
2023
Q1 		$2.75K Hold
77
– – ﹤0.01% 938
2022
Q4 		$2.91K Buy
+77
New +$3.24K ﹤0.01% 880

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Baker Avenue Asset Management's IONS Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2023, closing a stake of 77 shares — an estimated $3.49K sold.

Baker Avenue Asset Management first reported a position in IONS in Q4 2022 and held it in 4 quarters. The position peaked at $3.49K in Q3 2023. 363 funds tracked by Wall St. Rank hold IONS as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Ionis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 77 Ionis Pharmaceuticals shares in Q4 2023, an estimated $3.49K.
  • Baker Avenue Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's Ionis Pharmaceuticals position peaked at $3.49K in Q3 2023.
  • 363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.